Multiply Labs and GenScript Biotech Corporation have announced a strategic partnership to automate the cell isolation phase of cell therapy manufacturing, simplifying the process.
Multiply Labs and GenScript Biotech Corporation have embarked on a collaborative effort to automate the cell isolation phase of cell therapy manufacturing. This endeavor addresses a critical process in the industry, which involves the use of immunomagnetic beads for cell isolation. Traditionally, this task has been performed manually, presenting challenges due to the sensitivity of cells, intricate processes, and the need for precision. Manual handling, connection, and double-checking of complex closed-system consumable kits have been integral parts of this laborious process.
The collaboration leverages the strengths of both companies: Multiply Labs’ expertise in developing industry-leading automated manufacturing systems for individualized drugs and GenScript’s advanced cell isolation solution, the CytoSinct 1000. The CytoSinct 1000 is a GMP-grade solution capable of isolating up to 120X10^9 total cells within a single hour. By integrating this solution with Multiply Labs’ cell therapy robotic cluster, the collaboration aims to introduce the first fully automated solution for bead-based cell isolation.
One of the key advantages of this automated approach is its potential to streamline and simplify the cell therapy manufacturing process. Traditional manual methods are not only time-consuming but also prone to human error. The automated system, on the other hand, provides a direct connection to the patient’s residual muscles and peripheral nerves, delivering reliable, voluntary movement control signals. This direct connection enables unparalleled control of currently available advanced robotic prostheses and allows for simultaneous and independent movement of finger, wrist, and elbow joints.
Moreover, the automated system offers benefits in terms of scalability and efficiency. Once implemented, it could mitigate the risk of human error while simultaneously boosting cell therapy output. With the cell isolation phase automated, manufacturing operators and process scientists would be freed from the delicate and tedious manual tasks involved in the traditional manufacturing process. This would enable them to oversee the production of more therapies simultaneously, thereby driving significant efficiency gains.
Importantly, this automation technology does not require substantial modifications to existing manufacturing processes, making it easily adaptable for cell therapy manufacturers. The collaboration between Multiply Labs and GenScript Biotech Corporation represents a significant advancement in personalized medicine and the potential impact of cell therapies. It aligns with their shared goal of providing high-quality, affordable, and accessible specialty care to patients, ultimately reducing costs and expanding patient access to life-changing treatments.
